Stockreport

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 [Yahoo! Finance]

Lumos Pharma, Inc.  (LUMO) 
PDF for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of th [Read more]